



# 58th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)

Vienna, Austria, September 19–21, 2019

## Abstracts

---

Guest Editor

*Gabriele Häusler, Vienna, Austria*

Programme Organising Committee

Mehul Dattani, UK, *Chair and President Elect 2020*

Gabriele Häusler, Austria, *President 2019*

Stefan Riedl, Austria, *Vice President 2019*

Anders Juul, Denmark, *President Elect*

Evangelia Charmandari, Greece, *Chair of Clinical Practice Committee*

Nils Krone, UK, *Member*

Wolfgang Högler, UK, *Member*

Zdenek Sumnik, Czech Republic, *Member*

Dov Tiosano, Israel, *Member*

Local Organising Committee

Gabriele Häusler, *President*

Stefan Riedl, *Vice President*

Adalbert Raimann

Alois Gessl

Anton Luger

Birgit Rami-Merhar

Diana-Alexandra Ertl

Dieter Furthner

Elena Gottardi

Elisabeth Steichen-Gersdorf

Elke Fröhlich-Reiterer

Gerhard Koestl

Hannes Mühleder

Hildegard Jasser-Nitsche

Klaus Kapelari

Klaus Schmitt

Maria Fritsch

Michael Krebs

Peter Blümel

Walter Bonfig

Wolfgang Högler

---

## This publication was sponsored by

Alexion Pharma GmbH  
Ascendis Pharma  
Diurnal  
Ferring Pharmaceuticals  
Ipsen Pharma  
Kyowa Kirin International plc.  
Merck KGaA  
Novo Nordisk Healthcare AG  
Pfizer Inc.  
Rhythm  
Sandoz International GmbH

S. Karger  
Medical and Scientific Publishers  
Basel · Freiburg · Paris · London ·  
New York · Chennai · New Delhi ·  
Bangkok · Beijing · Shanghai · Tokyo ·  
Kuala Lumpur · Singapore · Sydney

### Disclaimer

The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

### All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2019 by S. Karger AG,  
P.O. Box, CH-4009 Basel (Switzerland)  
e-ISBN 978-3-318-06601-2

---

**KARGER**

E-Mail [karger@karger.com](mailto:karger@karger.com)  
[www.karger.com/hrp](http://www.karger.com/hrp)

## Contents

<b>Plenary Lectures</b>			
1	PL1	RANKL and RANK: Bone and Beyond	1
1	PL2	Light, Body Clocks and Sleep: Biology to New Therapeutics	2
1	PL3	Glucocorticoid Rhythms, Stress Response and the Brain from Neonates to Adults	3
1	PL4	Development of Novel Therapies for Obesity	4
1	PL5	Nutrition and the Reproductive Axis: Implications for the Control of Puberty	5
2	PL6	How to Reduce Waste and Increase Value in Translational Biomedical Research	6
2	PL7	Pituitary Gigantism - An Update	7
2	PL8	Novel Advances in Artificial Pancreas Development	8
<b>Symposia</b>			
3	S1	Novel Advances in Diabetes and Obesity	1.1–1.3
4	S2	Novel Mechanisms and Therapies in Bone and Growth Plate: Investing in the Future Health of Children	2.1–2.3
5	S3	Novel Insights in Our Understanding of Disorders of Sex Development: From Genes to Clinical Outcomes	3.1–3.3
5	S4	ISPAD/Complications of Type 1 Diabetes	4.1–4.3
6	S5	Impact of Genomics on Growth	5.1–5.3
7	S6	Endocrinology Meets Diversity: Transgender Youth	6.1–6.3
8	S7	Adrenal Insufficiency: New Mechanisms, New Therapies	7.1–7.3
10	S8	Autoimmunity: From Diagnosis to Treatment	8.1–8.3
11	S9	Heterogeneity of Paediatric Diabetes	9.1–9.3
12	S10	Brain Development and Sex: Is it Chromosomes or Hormones?	10.1–10.3
12	S11	Recent Advances in Our Understanding of Hypogonadotropic Hypogonadism	11.1–11.3
13	SS1	Special Symposia	1.1–1.2
<b>Meet the Expert</b>			
14	MTE1	Holistic Approach to the Individual with DSD	1
14	MTE2	The Interpretation of Abnormal Thyroid Function in Tests in Children and Adolescents	2
14	MTE3	New International Guidelines on Turner Syndrome	3
15	MTE4	Klinefelter Syndrome - When Should Testosterone Be Started	4
15	MTE5	Managing Endocrinopathies in McCune-Albright Syndrome	5
15	MTE6	Insulin Dosing for Real Meals	6
16	MTE7	Management of Graves' Disease	7
16	MTE8	Management of Neonatal Hypoglycaemia	8
<b>How Do I</b>			
17	HDI1	How Do I ... Session 1	1.1–1.3
17	HDI2	How Do I ... Session 2	2.1–2.3
<b>Novel Advances</b>			
19	NA1	Stem Cell Reprogramming, IPS Cells	1
19	NA2	Genomic Imprinting Analysis in Clinical Practice	2

	<b>Controversies</b>		
19	CON1	Does Obesity Need Tertiary Care Provision?	1.1–1.2
	<b>Young Investigators</b>		
19	YI1	(abstract not available)	1
20	YI2	Early Live Events and Postnatal Effects from Infancy to Childhood	2
	<b>Working Groups</b>	(abstract not available)	
20	WG1	DSD	1.1–1.6
20	WG2	Obesity	2.1–2.5
20	WG3	Bone & Growth Plate	3.1–3.6
20	WG4	Diabetes Technology	4.1–4.6
20	WG5	Paediatric and Adolescent Gynaecology	5.1–5.5
20	WG6	Gender Dysphoria	6.1–6.4
20	WG7	Turner Syndrome	7.1–7.5
20	WG8	ESPE Nursing and Allied Health Professionals	8.1–8.9
	<b>Endo-ERN Session</b>		
20	ERN1.1	Life Long Management of Childhood Craniopharyngioma	1
	<b>Free Communications</b>		
20	FC1	Diabetes and Insulin Session 1	1.1–1.6
23	FC2	Bone, Growth Plate and Mineral Metabolism Session 1	2.1–2.6
27	FC3	Multi-System Endocrine Disorders	3.1–3.6
30	FC4	Fat Metabolism and Obesity Session	4.1–4.6
33	FC5	Thyroid	5.1–5.6
37	FC6	Bone, Growth Plate and Mineral Metabolism Session 2	6.1–6.6
41	FC7	Diabetes and Insulin Session 2	7.1–7.6
44	FC8	Pituitary, Neuroendocrinology and Puberty Session 1	8.1–8.6
47	FC9	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	9.1–9.6
50	FC10	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	10.1–10.6
53	FC11	Pituitary, Neuroendocrinology and Puberty Session 2	11.1–11.6
56	FC12	Growth and Syndromes (to Include Turner Syndrome)	12.1–12.6
59	FC13	Adrenals and HP Axis	13.1–13.6
62	FC14	GH and IGF1	14.1–14.6
65	FC15	Late Breaking Abstracts	15.1–15.6
	<b>Rapid Free Communications</b>		
68	RFC1	Diabetes and Insulin Session 1	1.1–1.6
71	RFC2	Bone, Growth Plate and Mineral Metabolism Session 1	2.1–2.6
75	RFC3	Multi-System Endocrine Disorders	3.1–3.6
78	RFC4	Fat Metabolism and Obesity Session	4.1–4.6
81	RFC5	Thyroid	5.1–5.6
84	RFC6	Bone, Growth Plate and Mineral Metabolism Session 2	6.1–6.6
87	RFC7	Diabetes and Insulin Session 2	7.1–7.6
90	RFC8	Pituitary, Neuroendocrinology and Puberty Session 1	8.1–8.6
93	RFC9	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	9.1–9.6
96	RFC10	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	10.1–10.6
99	RFC11	Pituitary, Neuroendocrinology and Puberty Session 2	11.1–11.6
103	RFC12	Growth and Syndromes (to Include Turner Syndrome)	12.1–12.6
106	RFC13	Adrenals and HP Axis	13.1–13.6
109	RFC14	GH and IGF1	14.1–14.6
113	RFC15	Late Breaking Abstracts	15.1–15.6

<b>Prize Winners</b>			
116	HA1	Development of Testicular Organoids to Understand Disorders of Sex Development	1
116	HA2	Partial CRISPR/Cas9 IL1R1 & IFNGR1 Knock-Down Improves $\beta$ -Cell Survival and Function Under Cytokine-Induced Inflammation	2
<b>Poster Presentations</b>			
<b>Top 20 Poster</b>			
117		Top 20 Poster	T1–T20
<b>Poster Category 1</b>			
127	P1	Adrenals and HPA Axis	P1-1 – P1-13
134	P1	Bone, Growth Plate and Mineral Metabolism	P1-14 – P1-24
139	P1	Diabetes and Insulin	P1-25 – P1-38
146	P1	Fat, Metabolism and Obesity	P1-39 – P1-63
159	P1	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	P1-64 – P1-71
163	P1	GH and IGFs	P1-72 – P1-83
169	P1	Growth and Syndromes (to Include Turner Syndrome)	P1-84 – P1-96
176	P1	Pituitary, Neuroendocrinology and Puberty	P1-97 – P1-120
187	P1	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P1-121 – P1-142
197	P1	Thyroid	P1-143 – P1-155
204	P1	Adrenals and HPA Axis	P1-156 – P1-167
210	P1	Bone, Growth Plate and Mineral Metabolism	P1-168 – P1-177
216	P1	Diabetes and Insulin	P1-178 – P1-190
222	P1	Fat, Metabolism and Obesity	P1-191 – P1-203
228	P1	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	P1-204 – P1-211
232	P1	GH and IGFs	P1-212 – P1-222
237	P1	Growth and Syndromes (to Include Turner Syndrome)	P1-223 – P1-235
244	P1	Multisystem Endocrine Disorders	P1-236 – P1-248
251	P1	Pituitary, Neuroendocrinology and Puberty	P1-249 – P1-260
257	P1	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P1-261 – P1-282
270	P1	Thyroid	P1-283 – P1-295
277	P1	Adrenals and HPA Axis	P1-296 – P1-307
283	P1	Diabetes and Insulin	P1-308 – P1-333
296	P1	Fat, Metabolism and Obesity	P1-334 – P1-358
308	P1	GH and IGFs	P1-359 – P1-370
314	P1	Growth and Syndromes (to Include Turner Syndrome)	P1-371 – P1-393
325	P1	Pituitary, Neuroendocrinology and Puberty	P1-394 – P1-408
332	P1	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P1-409 – P1-419
338	P1	Thyroid	P1-420 – P1-432
345	P1	Late Breaking Posters	LB1 – LB28
<b>Poster Category 2</b>			
359	P2	Adrenals and HPA Axis	P2-1 – P2-25
371	P2	Bone, Growth Plate and Mineral Metabolism	P2-26 – P2-61
389	P2	Diabetes and Insulin	P2-62 – P2-104
407	P2	Fat, Metabolism and Obesity	P2-105 – P2-142
426	P2	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	P2-143 – P2-152
431	P2	GH and IGFs	P2-153 – P2-174
442	P2	Growth and Syndromes (to Include Turner Syndrome)	P2-175 – P2-202
455	P2	Multisystem Endocrine Disorders	P2-203 – P2-216
461	P2	Pituitary, Neuroendocrinology and Puberty	P2-217 – P2-243
474	P2	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P2-244 – P2-275
489	P2	Thyroid	P2-276 – P2-301

	<b>Poster Category 3</b>		
501	P3	Adrenals and HPA Axis	P3-1 – P3-27
514	P3	Bone, Growth Plate and Mineral Metabolism	P3-28 – P3-46
521	P3	Diabetes and Insulin	P3-47 – P3-95
541	P3	Fat, Metabolism and Obesity	P3-96 – P3-130
557	P3	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	P3-131 – P3-137
560	P3	GH and IGFs	P3-138 – P3-150
565	P3	Growth and Syndromes (to Include Turner Syndrome)	P3-151 – P3-178
579	P3	Multisystem Endocrine Disorders	P3-179 – P3-189
584	P3	Pituitary, Neuroendocrinology and Puberty	P3-190 – P3-216
596	P3	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P3-217 – P3-248
610	P3	Thyroid	P3-249 – P3-264
617	P3	Late Breaking Posters	P3-265 – P3-333
650	<b>Author Index</b>		

HOMA index, CC / CV ratio have been obtained. Spearman's correlation coefficient was calculated between NC, WC, BMI and laboratory values.

**Results:** All obese children had a NC > 95th percentiles for sex and age (cut off: 30.5 - 46.5 cm), mean value  $35.97 \pm 4.2$  cm. NC correlated significantly with BMI ( $R = 0.66832$ ,  $P = 0.0001$ ), WC ( $R = 0.69944$ ,  $P = 0.00005$ ) and blood uric acid (UA) values ( $R = 0.53685$ ,  $P = 0.04777$ ). UA was > 6.5 mg/dL in 30% of our studied sample. No correlation ( $p > 0.05$ ) between NC and inflammatory indexes, transaminases, HOMA index, lipid profile, SBP/DBP, hepatic steatosis was found.

**Conclusions:** This study of our series shows that NC could be used as an alternative to BMI and WC, to identify PO and related HMC risk factors.

#### P2-139

### The prevalence of elevated blood pressure and hypertension in Korean adolescents, based on the guidelines of Endocrine Society and American Academy of Pediatrics

*In-Hyuk Chung<sup>1</sup>, Young Hee Hong<sup>2</sup>, Sochung Chung<sup>3</sup>*

<sup>1</sup>Department of pediatrics, National Health Insurance Service Ilsan Hospital, Ilsan, Korea, Republic of. <sup>2</sup>Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon, Korea, Republic of.

<sup>3</sup>Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea, Republic of

**Purpose:** Childhood obesity epidemic leads an interest of pre-stage of hypertension; higher/elevated blood pressure (BP) status which BP numbers are lower than the criteria for diagnosing hypertension. In 2017, the clinical practice guidelines for pediatric BP management were published separately by Endocrine Society (ES) and American Academy of Pediatrics (AAP). The aims of this study are to evaluate the prevalence of elevated blood pressure (EBP) including hypertension (HTN) and the difference of those according to the guidelines in Korean adolescents.

**Methods:** We analyzed data of 1166 adolescents aged 13-17 years (male/female 611/555) from the Korea National Health and Nutrition Examination Survey (2014-2016). BP group were categorized as normal, EBP and HTN according to each guideline and prevalence of EBP and HTN were analyzed and compared. In ES guideline BP of >90<sup>th</sup> percentile to <95<sup>th</sup> percentile or >120/80 is prehypertension, BP  $\geq 95^{\text{th}}$  percentile to <99<sup>th</sup> percentile + 5 mm Hg is stage 1 HTN and BP  $\geq 99^{\text{th}}$  percentile + 5 mm Hg is stage 2 HTN. In AAP guideline, elevated BP is defined as >120/80 to 129/80 mm Hg, Stage 1 HTN is 130/80 to 139/89 mm Hg and Stage 2 HTN is BP  $\geq 140/90$  mm Hg

**Results:** The average age was 14.97 years and body mass index (BMI) z-score was 0.06 and 0.08 in boys and girls, respectively. 23% of boys and 22% of girls were overweight including obesity. 11.8% of boys and 31.5% of girls were central obesity defined by waist circumference (WC) above 90th percentile for gender and age. Systolic BP was 111.99 and 106.13 mmHg, and diastolic BP was 67.39 and 66.63 mmHg in boys and girls, respectively. BP was positively correlated with BMI z-score and WC percentile.

The prevalence of EBP was 36.5% vs. 25.2% according to ES and AAP, respectively in boys and 25.1% vs. 10.1% in girls. HTN prevalence was 23.7% vs. 12.3% in boys and 18.9% vs. 5.4% in girls. The prevalence of EBP and HTN were different by the guideline, in each gender. Prior to diagnosis of hypertension, 5% to 13% of adolescents could initiate life style intervention by EBP criteria.

**Conclusion:** One in three or four of Korean adolescents has increased blood pressure and the prevalence of EBP and HTN were different according to ES and AAP guideline. Early therapeutic interventions such as life style modification including diet and physical activity should be started in adolescents with EBP.

#### P2-140

### PEDOBESITY: Development of Intelligent Multi-level Information Systems and Specialized Artificial Intelligence Algorithms for Personalized Management of Obesity in Childhood and Adolescence

*Penio Kassari<sup>1,2</sup>, Antonis Billiris<sup>3</sup>, Haralampos Karanikas<sup>3,4</sup>, Eleftherios Thireos<sup>4</sup>, Nikolaos Drakoulis<sup>5</sup>, Ioannis Manios<sup>6</sup>, Evangelia Charmandari<sup>1,2</sup>*

<sup>1</sup>Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

<sup>2</sup>Out-patient Clinic for the Prevention and Management of Overweight and Obesity, Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece. <sup>3</sup>Datamed SA, Athens, Greece. <sup>4</sup>The Athens Medical Society, Athens, Greece. <sup>5</sup>Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece. <sup>6</sup>Department of Nutrition & Dietetics, School of Health Science & Education, Harokopio University of Athens, Kallithea - Athens, Greece

**Background:** Obesity in childhood and adolescence represents a major health problem of our century. In Greece, more than 30-35% of children and adolescents are currently overweight or obese.

**Objective:** To evaluate and further develop the 'National Registry for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence' in order to provide personalized intervention programs for overweight and obese children and adolescents using intelligent information systems and support systems.

**Methodology:** The project is part of the Operational Program "Competitiveness, Entrepreneurship & Innovation, EPAnEK 2014-2020" (project code: T1EDK-01386, MIS: 5030543, Acronym: PEDOBESITY), which is co-funded by Greece and the European Union, and represents continuation of the Program "Development of a National System for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence in Greece". The main innovative actions include: (1) Collection and analysis of clinical, hematological, biochemical, endocrinological and genetic data of overweight and obese children and adolescents; (2) Detection of polymorphisms associated with obesity, diabetes

type 2, antioxidant ability and body mass index; (3) Development of a specific obesity-risk algorithm by linking each genotype to the patient's data, as well as published information on how it affects body weight at clinical or genetic level; (4) Development of interconnected online and mobile applications to integrate the ecosystem of applications for childhood obesity. Applications will include development and expansion of the Electronic Health File (EHR) of the "National Registry for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence", Patient Access Subsystem and Online Support, as well as mobile application for children, adolescents and their parents; (5) The development of an intelligent data management platform (in full interoperability with the "National Registry for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence") using the innovative methodology of Fuzzy Cognitive Maps and modeling techniques from medical data analysis in order to provide personalized treatment guidelines.

**Results:** Our goal is to reduce overweight and obesity rates in Greece by at least 20% within 5 years following implementation of the project.

**Conclusions:** These research actions are expected to play an important role in the effective management of childhood obesity.

#### P2-141

### Metabolic syndrome risk assessment in Indian children and adolescents

*Vasundhara Chugh, Archana Arya*

Sir Ganga Ram Hospital, New Delhi, India

**Objective:** To assess the risk of metabolic syndrome (MS) in children and adolescents as per the recommendation based on the age and sex-specific reference curves for Waist Circumference (WC) for Indian children by Khadilkar et al.

**Study design:** A total of 370 children (200 girls, 170 boys) aged 6 to 18years coming for regular checkups to our center from January 2016 to March 2019 with WC >70<sup>th</sup> percentile were enrolled. All children were assessed for metabolic syndrome risk factors with respect to BMI, BP measurements, and levels of fasting triglycerides, high-density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL), and fasting plasma glucose were recorded for all patients.

Prevalence rates of MS in the pediatric age group vary depending on the criteria used. **The International Diabetes Federation's** (IDF) definition of MS in children has been divided according to the following age groups (6-10 years, 10-16 years, and 16+ years). For those aged 6 to <10yr, though MS cannot be diagnosed but further measurements were made in children with a family history of metabolic syndrome (MS), type 2 diabetes mellitus (T2DM), dyslipidemia, cardiovascular disease, hypertension and/or obesity.

**Results:** As per IDF definition, 64 out of 240 (26.66%) children in the 10 to 18 year age group met the criteria for pediatric metabolic syndrome.

Age group	10 to <16yr (n=217)	16-18yr (n=23)
Percentage meeting the IDF criteria	23.5%	56.52%

Those aged 6 to <10years with a family history of MS, T2DM, dyslipidemia, cardiovascular disease, hypertension and/or obesity were also evaluated for metabolic syndrome. Eighteen out of 130 children (13.84%) met the criteria for metabolic syndrome as per IDF definition in this age group.

Children were also evaluated for MS as per the modified definition proposed by **NCEP/ATPIII**. As per this definition, 63 out of 158 (39.8%) children in the age group of 12-18yr met the criteria for pediatric metabolic syndrome.

Gender	Males (n=78)	Females (n=80)
Percentage meeting the NECP criteria	34.61%	45%

**Conclusion:** Overall, 39.8% and 26.66% children met the NCEP/ATPIII & IDF criteria respectively. The low incidence of MS with IDF definition may be due to the cut-off value used for blood pressure as systolic BP  $\geq 130$  or diastolic BP  $\geq 85$ mmHg for all age groups.

The WC percentiles proposed for Indian children are useful in identifying children with metabolic syndrome. Early detection and management is vital in halting the progression of this syndrome pathway in children.

#### P2-142

### Vitamin D status in obese children and its relationship with leptin and adiponectin

*Mona Nourbakhsh<sup>1</sup>, Mitra Nourbakhsh<sup>2</sup>, Maryam Razzaghy Azar<sup>1,3</sup>*

<sup>1</sup>H.Aliasghar children's Hospital, Iran university of medical sciences, Tehran, Iran, Islamic Republic of. <sup>2</sup>Department of biochemistry, faculty of medicine, Iran University of Medical /sciences, Tehran, Iran, Islamic Republic of. <sup>3</sup>Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute, Tehran University of medical Sciences, Tehran, Iran, Islamic Republic of

**Introduction:** obesity is a major health problem worldwide and its incidence is increasing annually. Adipose tissue produces and regulates many hormones and cytokines which have relationship with obesity comorbidity. Serum level of vitamin D has been previously reported to have a negative relationship with obesity.

**Objective:** To evaluate the relationship between vitamin D status and leptin, adiponectin, lipid profile and Insulin resistance in obese children.

**Material & Method:** A total of 61 children including 32 obese (BMI > 95<sup>th</sup> percentile according to CDC curves for sex and age) and 29 normal weight subjects, aged 4-17 year, were randomly enrolled in this study. After clinical evaluation and anthropometric measurements, fasting serum level of vitamin D, leptin and adiponectin were assessed using ELISA method. Fasting plasma level of total cholesterol, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), Triglyceride (TG), glucose and insulin were measured with colorimetric kits and homeostasis model assessment of insulin resistance (HOMA-IR) was calculated.